DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
|
DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Results Insider information pursuant to Article 17 MA
Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter Berlin, 27 July 2022. Based on initial, unaudited assessments, revenues of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) for the second quarter increased by 26% from 45,3 to 56,9 mm EUR. Compared to last year’s second quarter, the net income only increased by around 5% from 8,5 to 8,9 mm EUR. However, the direct comparison is misleading, as untypically low taxes were recognized in the previous year due to special effects. Using Earnings before Taxes as a comparator, profits in the second quarter of 2022 rose by around 60% from 8,7 to 13,9 mm EUR. Prime reason for the profit increase, apart from favourable exchange rates, were stronger sales in the Isotope segment of industrial products and radiopharmaceuticals. The complete figures for the second quarter 2022 will be published on 11 August 2022.
For enquiries please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
27-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1407141 |
| End of Announcement | DGAP News Service |
|
|
1407141 27-Jul-2022 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Eckert & Ziegler Strahlen- und Medizintechnik AG, ohne Sell-Einschätzungen.
Das Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 48.4 €.
